Valuation: Compugen Ltd.

Market Cap 27Cr 23Cr 22Cr 20Cr 38Cr 2.59TCr 38Cr 257.48Cr 100.23Cr 1.31TCr 102.08Cr 100Cr 4.33TCr P/E 2026 *
-10.3x
P/E 2027 * -10.4x
Enterprise Value 27Cr 23Cr 22Cr 20Cr 38Cr 2.59TCr 38Cr 257.48Cr 100.23Cr 1.31TCr 102.08Cr 100Cr 4.33TCr EV / Sales 2026 *
29.4x
EV / Sales 2027 * 35.1x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-51.68%-9.82% - - 27Cr
-0.13%+2.18%+2.35%+24.46% 5.17TCr
-0.09%-2.14%+492.60%+537.84% 4.53TCr
-0.32%+8.08%+37.97%+18.45% 4.27TCr
+1.18%+1.96%+21.95%+89.69% 4.28TCr
-2.27%-3.02%+14.22%+51.50% 3.29TCr
-0.96%+4.03%+31.55%+136.34% 1.71TCr
+0.41%+1.66% - - 1.66TCr
0.00%+4.84%+13.03%+30.79% 1.5TCr
-0.31%+6.61%+81.37%+48.53% 1.42TCr
Average -0.55%+2.97%+86.88%+117.20% 3.09TCr
Weighted average by Cap. -0.25%+2.74%+104.56%+135.43%

Financials

2026 *2027 *
Net sales 92.39L 79.17L 74.18L 67.76L 1.28Cr 88Cr 1.29Cr 8.75Cr 3.41Cr 44Cr 3.47Cr 3.39Cr 147.16Cr 77.5L 66.41L 62.23L 56.84L 1.07Cr 74Cr 1.08Cr 7.34Cr 2.86Cr 37Cr 2.91Cr 2.85Cr 123.45Cr
Net income -2.65Cr -2.27Cr -2.12Cr -1.94Cr -3.66Cr -252.3Cr -3.7Cr -25Cr -9.76Cr -127.29Cr -9.94Cr -9.72Cr -421.55Cr -2.7Cr -2.31Cr -2.16Cr -1.98Cr -3.73Cr -256.93Cr -3.77Cr -26Cr -9.94Cr -129.63Cr -10Cr -9.9Cr -429.28Cr
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-